在年轻白人欧洲人和南亚男性中,在体重增加之前和之后,HDL蛋白质的组成不同
Jack D Beazer1, James McLaren1, Christina Christoffersen2,3
1School of Cardiovascular and Metabolic Health, Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, U.K.
Clinical science (London, England : 1979)
|December 19, 2025
概括
与欧洲人 (欧盟) 相比,南亚人 (SA) 呈现出明显的高密度脂蛋白 (HDL) 蛋白质配置,显示炎症标志物增加和脂质代谢受损. 即使体重增加后,这些差异仍然存在,突出了心血管疾病风险因素的种族差异.
科学领域:
- 心血管疾病研究研究
- 代谢健康 代谢健康
- 蛋白质组学是指蛋白质组学.
背景情况:
- 英国的南亚人 (SAs) 与白人欧洲人 (EUs) 相比,面临心血管疾病 (CVD) 和2型糖尿病 (T2DM) 的风险更高.
- 在SA中较低的高密度脂蛋白胆固醇 (HDL-C) 度有助于心血管疾病风险.
- 之前的研究表明,在体重增加后,SA和欧盟男性之间的身体组成和胰岛素抵抗有种族差异.
研究的目的:
- 调查SA和欧盟男性之间的HDL蛋白质组成,子类分布和体外血管功能的种族差异.
- 评估适度体重增加如何影响这两个种族群体的高密度胆固醇特征.
- 确定HDL组成和观察到的健康差异之间的潜在机制联系.
主要方法:
- 纳米液体染色学双重质谱法 (LC-MS) 用于无标签量化HDL蛋白质组成.
- 原生凝电泳用于HDL亚类分布分析.
- 在体外测试测量HDL偏酶-1 (PON-1) 活性和内皮细胞中的抗炎功能.
主要成果:
- 与基线和体重增加后的欧盟相比,SAS在HDL中显示出更高的免疫和炎症相关蛋白质水平.
- 在SAS中观察到与脂质代谢相关的有害蛋白质配置 (例如,较低的apoA-IV,apoF;较高的apoC-III).
- 在两个族群之间,在HDL亚类分布或体外血管功能方面没有发现显著差异.
结论:
- 在SA中的HDL蛋白组成反映了系统生理学,表明脂质代谢受损.
- 高密度胆固醇蛋白质 (HDL) 样本的种族差异可能成为南亚人心血管疾病风险增加的机制性标记.
- 向高密度胆固醇成分可能为降低风险人群心血管风险提供新的治疗策略.
更多相关视频
09:52Investigation of Beige Fat Biology and Metabolism Using the CRISPR SunTag-p65-HSF1 Activation System
Published on: January 6, 2023
2.7K
08:13Robust Comparison of Protein Levels Across Tissues and Throughout Development Using Standardized Quantitative Western Blotting
Published on: April 9, 2019
14.8K
相关概念视频
The Y Chromosome Determines Maleness
7.8K
The Y chromosome is a sex chromosome found in several vertebrates and mammals, including humans. In addition to 22 pairs of autosomes, the human males have one X chromosome and one Y chromosome. In these organisms, the presence or absence of the Y chromosome determines the development of male traits.
Evolution
Around 300 million years ago, the two sex chromosomes diverged from two identical autosomal chromosomes. Over time, the Y chromosome has lost most of its genes, shrinking in size....
Evolution
Around 300 million years ago, the two sex chromosomes diverged from two identical autosomal chromosomes. Over time, the Y chromosome has lost most of its genes, shrinking in size....
7.8K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
280
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
280
